Citations

Mayo Clinic

Showing 10 of 108537 citations.

Establishing hemolysis, icterus, and lipemia interference limits for body fluid chemistry analytes measured on the Roche cobas instrument
Block, Darci R , Lasho, Michael A., Meeusen, Jeffrey W. , Donato, Leslie J.

American Journal of Clinical Pathology | May 6, 2024 | Volume: 162 | Issue: 4 | Pages: 356-368

10.1093/ajcp/aqae040 | PMID 38709595 Get It

Abstract Objectives The aims of this study were to (1) establish the maximum allowable interference limits for hemolysis, lipemia, and icterus for chemistry analytes tested in body fluid samples and (2) assess the effectiveness of serial dilution to mitigate spectral interferences. Methods Residual body fluids from clinically ordered testing were mixed (<10% by volume) with stock solutions of interferent (spiked) and compared with a control spiked with an equal volume of 0.9% saline. The analytes were measured on the Roche cobas c501 instrument. Difference and percentage difference were calculated and compared with allowable total error limits. A subset of samples were serially diluted with 0.9% saline. Mean (SD) difference and percentage difference were calculated. Results The interference thresholds were lower than the package insert for lactate dehydrogenase, cholesterol, triglycerides, and total protein for hemolysis; amylase, cholesterol, and total protein for icterus; and albumin for lipemia. Only cholesterol and triglyceride results returned to baseline upon dilution of icteric samples. Conclusions Interference thresholds in body fluids were lower than blood for 6 analytes. Diluting interferences that surpass these limits does not produce reliable results that are comparable to the baseline results before spiking in the interferent.
Low-profile mechanical thrombectomy devices for large vessel occlusion in pediatric ischemic stroke
Oushy, Soliman , Garton, Andrew , See, Alfred P. , Oushy, Soliman H , Orbach, Darren B.

Journal of NeuroInterventional Surgery | May 6, 2024 | Volume: 17 | Issue: 6 | Pages: 620-624

10.1136/jnis-2024-021574 | PMID 38719443 Get It

Background Mechanical thrombectomy (MT) is a well-established treatment modality for large vessel occlusion (LVO) in adults, but there are limited data in the pediatric population. The rarity of the condition makes prospective trial design difficult, and therefore evaluation of MT devices and outcomes is sparse. In pediatric LVO cases, some newer devices may be appropriate for use in revascularization procedures. Furthermore, illustrative specific device-access combinations have rarely been presented in young patients under the age of 5 years. Methods This was a single institution experience in intracranial MT procedures for pediatric acute ischemic stroke (AIS). A given procedure was included if there was an attempt at MT between 2015 and 2023. Results Sixteen endovascular procedures were performed in 15 patients with AIS, with a mean age of 7.4 years; eight patients were <5 years of age. MT was attempted in 15/16 (93.7%) procedures, including 11 (73.3%) in the anterior circulation and four (26.7%) in the posterior circulation; one case recanalized after medical treatment. The most common MT techniques were combined aspiration with a stentriever (n=10, 66.7%) and aspiration alone (n=3, 20%). Traditional stentrievers (4–6 mm) were used in seven cases and low-profile stentrievers in four cases. Improved reperfusion was achieved in all low-profile stentriever cases. Reperfusion of modified Thrombolysis in Cerebral Infaction ≥2b was obtained in 73.3% of cases, including 72.7% of those in which a stentriever was used. Conclusions Low-profile thrombectomy devices may achieve similar revascularization results to other approaches in challenging clinical scenarios observed in younger children.
From the Editor-in-Chief’s Desk: Precision Classification and Treatment of Early Life Mood Disorders for Improved Outcomes
Croarkin, Paul E. , Croarkin, Paul E

Journal of Child and Adolescent Psychopharmacology | May 6, 2024 | Volume: 34 | Issue: 4 | Pages: 165-166

10.1089/cap.2024.0032 | PMID 38709161 Get It

Generation of a Human Induced Pluripotent Stem Cell Line Expressing a Magnetic Resonance Imaging Reporter Gene
Son, Yura , Li, Pengsheng , Ortega, Dakota, Qiu, Huiliang , Prachyl, Hannah, Zhu, Wuqiang , Zhu, Wuqiang , Son, Yura , Yang, Ming

Small Methods | May 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/smtd.202301764 | PMID 38708688 Get It

AbstractThe objective of the current study is to develop a new method for tracking transplanted human induced pluripotent stem cells‐derived cardiomyocytes (hiPSC‐CMs) using magnetic resonance imaging (MRI). The CRISPR/dCas9 activation system is employed to overexpress ferritin heavy chain (FHC) in hiPSC‐CMs. The mRNA and protein expression of FHC in hiPSC and hiPSC‐CMs significantly increased after transfection. Iron chloride does not affect the cell viability in a concentration range from 0 to 2000 µm. hiPSCs overexpressing FHC (hiPSC‐ FHCOE) and hiPSC‐CMs overexpressing FHC (hiPSC‐CM‐FHCOE) significantly enhanced cellular uptake of iron chloride but with no changes in electrophysiological properties compared to hiPSC‐CM‐Control. Furthermore, hiPSC‐CM‐FHCOE presented robust contrast and lower T2* values, signifying their potential as highly effective candidates for cardiac MRI. Next, hiPSC‐CM‐FHCOE is injected into mouse hearts and after 3 days of transplantation, MR images are obtained. hiPSC‐CM‐FHCOE cells exhibited clear signals in the hearts with lower T2* and rapid signal decay. Collectively, data from this proof‐of‐concept study demonstrated that endogenous labeling with FHC in hiPSC‐CMs can be a potent strategy for enhancing the accuracy of cardiac MRI. This technology represents a significant step forward in tracking the transplanted hiPSC‐CMs in the hearts of live animals.
Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies
Miller, Carly D. , Zorko, Nicholas A. , Elliott, Andrew , Makovec, Allison , Radovich, Milan , Heath, Elisabeth I. , Agarwal, Neeraj , McKay, Rana R. , Garje, Rohan , Bastos, Bruno , Orme, Jacob J. , Nabhan, Chadi , Dehm, Scott M. , Hwang, Justin H. , Lozada, John R , Zorko, Nicholas A , Elliott, Andrew , Makovec, Allison , Radovich, Milan , Heath, Elisabeth I , Agarwal, Archana M , McKay, Rana R , Garje, Rohan , Bastos, Bruno R , Hoon, Dave S B , Orme, Jacob J , Sartor, A Oliver , VanderWalde, Ari , Nabhan, Chadi , Sledge, George W , Shenderov, Eugene , Dehm, Scott M , Lou, Emil , Miller, Jeffrey S , Hwang, Justin H , Antonarakis, Emmanuel S , Hoon, Dave S.�B. , Sartor, Oliver , Vanderwalde, Ari M. , Sledge, George W. , Shenderov, Eugene , Lou, Emil , Miller, Jeffrey S. , Antonarakis, Emmanuel S.

Cancer Research Communications | May 6, 2024 | Volume: 4 | Issue: 5 | Pages: 1369-1379

10.1158/2767-9764.crc-23-0546 | PMID 38709075 Get It

Abstract B7-H3 (CD276) is a transmembrane glycoprotein of the B7 immune checkpoint superfamily that has emerged as a promising therapeutic target. To better understand the applicability of B7-H3–directed therapies, we analyzed 156,791 samples comprising 50 cancer types to interrogate the clinical, genomic, transcriptomic, and immunologic correlates of B7-H3 mRNA expression. DNA (592-gene/whole-exome) and RNA (whole-transcriptome) sequencing was performed from samples submitted to Caris Life Sciences. B7-H3 high versus low expression was based on top and bottom quartiles for each cancer type. Patients’ overall survival was determined from insurance claims data. Pathway analysis was performed using gene set enrichment analyses. Immune cell fractions were inferred using quanTIseq. B7-H3 is expressed across several human malignancies including prostate, pancreatic, ovarian, and lung cancers. High B7-H3 expression is associated with differences in overall survival, possibly indicating a prognostic role of B7-H3 for some cancers. When examining molecular features across all cancer types, we did not identify recurrent associations between B7-H3 expression and genetic alterations in TP53, RB1, and KRAS. However, we find consistent enrichment of epithelial-to-mesenchymal transition, Wnt, TGFβ, and Notch signaling pathways. In addition, tumors with high B7-H3 expression are associated with greater proportions of M1 macrophages, but lower fractions of CD8+ T cells. We have begun to define the genomic, transcriptomic, clinical, and immunologic features associated with B7-H3 expression in 50 cancer types. We report novel clinical and molecular features of B7-H3–high tumors which may inform how current B7-H3 therapeutics should be deployed and prioritized. Significance: B7-H3–targeting therapeutics have shown promising results in initial clinical trials. In this pan-cancer analysis of B7-H3 mRNA expression, we found that B7-H3 exhibits robust expression in many common cancer types. These results may inform further development of B7-H3–targeting therapeutics and may guide clinical decisions for patients with limited treatment options.
Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence
Sinicrope, Frank A. , Nelson, Garth D. , Saberzadeh-Ardestani, Bahar , Segovia, Diana I. , Graham, Rondell P. , Wu, Christina , Shivji, Sameer , Savage, Paul , Buchanan, Daniel D. , Phipps, Amanda I. , Swallow, Carol J. , Gallinger, Steven , Grant, Robert C. , Pai, Reetesh K. , Sinicrope, Stephen N. , Yan, Dongyao , Shanmugam, Kandavel , Conner, James , Cyr, David P. , Kirsch, Richard , Banerjee, Imon , Alberts, Steve R., Pai, Rish K. , Hagen, Catherine E , Shivji, Sameer , Savage, Paul , Buchanan, Daniel D , Jenkins, Mark A , Phipps, Amanda I , Swallow, Carol , Marchand, Loïc Le , Gallinger, Steven , Grant, Robert C , Pai, Reetesh K , Sinicrope, Stephen N , Yan, Dongyao , Shanmugam, Kandavel , Conner, James , Cyr, David P , Kirsch, Richard , Banerjee, Imon , Alberts, Steven R , Shi, Qian , Pai, R K , Graham, Rondell P , Sinicrope, Frank A , Wu, Christina , Hagen, Catherine E. , Jenkins, Mark A. , Marchand, Loı̈c Le , Alberts, Steven R. , Shi, Qian

Cancer Research Communications | May 6, 2024 | Volume: 4 | Issue: 5 | Pages: 1344-1350

10.1158/2767-9764.crc-24-0031 | PMID 38709069 Get It

Abstract Deep learning may detect biologically important signals embedded in tumor morphologic features that confer distinct prognoses. Tumor morphologic features were quantified to enhance patient risk stratification within DNA mismatch repair (MMR) groups using deep learning. Using a quantitative segmentation algorithm (QuantCRC) that identifies 15 distinct morphologic features, we analyzed 402 resected stage III colon carcinomas [191 deficient (d)-MMR; 189 proficient (p)-MMR] from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy. Results were validated in an independent cohort (176 d-MMR; 1,094 p-MMR). Association of morphologic features with clinicopathologic variables, MMR, KRAS, BRAFV600E, and time-to-recurrence (TTR) was determined. Multivariable Cox proportional hazards models were developed to predict TTR. Tumor morphologic features differed significantly by MMR status. Cancers with p-MMR had more immature desmoplastic stroma. Tumors with d-MMR had increased inflammatory stroma, epithelial tumor-infiltrating lymphocytes (TIL), high-grade histology, mucin, and signet ring cells. Stromal subtype did not differ by BRAFV600E or KRAS status. In p-MMR tumors, multivariable analysis identified tumor-stroma ratio (TSR) as the strongest feature associated with TTR [HRadj 2.02; 95% confidence interval (CI), 1.14–3.57; P = 0.018; 3-year recurrence: 40.2% vs. 20.4%; Q1 vs. Q2–4]. Among d-MMR tumors, extent of inflammatory stroma (continuous HRadj 0.98; 95% CI, 0.96–0.99; P = 0.028; 3-year recurrence: 13.3% vs. 33.4%, Q4 vs. Q1) and N stage were the most robust prognostically. Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphologic differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis. Significance: A deep learning algorithm can quantify tumor morphologic features that may reflect underlying mechanisms driving prognosis within MMR groups. TSR was the most robust morphologic feature associated with TTR in p-MMR colon cancers. Extent of inflammatory stroma and N stage were the strongest prognostic features in d-MMR tumors. TIL density was not independently prognostic in either MMR group.
A Method for Continuous Surgeon Improvement in Rectal Cancer
Violante, Tommaso , Merchea, Amit , Dozois, Eric J. , Dozois, Eric, Violante, Tommaso , Ferrari, Davide , Vierkant, Robert A. , Larson, David W.

Annals of Surgery | May 6, 2024 | Volume: 282 | Issue: 2 | Pages: 304-310

10.1097/sla.0000000000006330 | PMID 38708881 Get It

Objective: To develop and analyze a risk-adjusted cumulative sum (RA-CUSUM) chart as a potential method to monitor individual surgeon performance in robotic total mesorectal excision (TME) for rectal cancer. Background: Currently, surgeons lack real-time tools to monitor and enhance their performance beyond residency completion. While national quality programs exist, granular, individual-level data are crucial for continuous improvement. Previous studies suggest cumulative sum charts hold promise in identifying performance trends and outliers. Methods: This retrospective study analyzed data from 640 robotic TME cases performed by 12 surgeons at 2 institutions. RA-CUSUM charts were generated for 3 outcomes: (1) complications, (2) operative time, and (3) length of stay. Results: The overall RA-CUSUM curves for operative time and complications showed an initial learning phase, followed by a plateau or downward slope, indicating proficiency or improvement. However, individual surgeon curves revealed significant heterogeneity. Three surgeons consistently excelled in operative time, while 5 minimized complications most effectively. Potential quality improvement could be implemented to drive performance toward positive outliers. No differences were found in unadjusted outcomes, including conversion, number of lymph nodes harvested, and positive circumferential margins. Conclusions: The RA-CUSUM chart is a promising method for identifying individual surgeon performance in robotic TME. It could help surgeons, teams, and leaders identify improvement areas and benchmark themselves against positive outliers. Further studies are needed to explore the potential of RA-CUSUM for implementing interventions to improve surgical quality.
Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes
Hambright, William S. , Duke, Victoria R. , Goff, Adam D., Goff, Alex W., Minas, Lucas T., Kloser, Heidi , Huard, Charles, Guo, Ping , Lu, Aiping , Mitchell, John M., Netto, Jair Machado Espindola, Niedernhofer, Laura J. , Kirkland, James L. , Bahney, Chelsea S. , Huard, Johnny , Lu, Aiping , Tchkonia, Tamara, Espindola Netto, Jair M , Robbins, Paul D , Niedernhofer, Laura J , Bahney, Chelsea S , Philippon, Marc , Huard, Johnny , Duke, Victoria , Goff, Alexander , Gao, Xueqin , Mitchell, John, Mullen, Michael T. , Su, Charles A. , Tchkonia, Tamar , Espíndola‐Netto, Jair Machado , Robbins, Paul D. , Philippon, Marc J.

Aging Cell | May 6, 2024 | Volume: 23 | Issue: 5 | Pages: No page available

10.1111/acel.14113 | PMID 38708778 Get It

Abstract Chronic conditions associated with aging have proven difficult to prevent or treat. Senescence is a cell fate defined by loss of proliferative capacity and the development of a pro‐inflammatory senescence‐associated secretory phenotype comprised of cytokines/chemokines, proteases, and other factors that promotes age‐related diseases. Specifically, an increase in senescent peripheral blood mononuclear cells (PBMCs), including T cells, is associated with conditions like frailty, rheumatoid arthritis, and bone loss. However, it is unknown if the percentage of senescent PBMCs associated with age‐associated orthopedic decline could be used for potential diagnostic or prognostic use in orthopedics. Here, we report senescent cell detection using the fluorescent compound C 12 FDG to quantify PBMCs senescence across a large cohort of healthy and osteoarthritic patients. There is an increase in the percent of circulating C 12 FDG + PBMCs that is commensurate with increases in age and senescence‐related serum biomarkers. Interestingly, C 12 FDG + PBMCs and T cells also were found to be elevated in patients with mild to moderate osteoarthritis, a progressive joint disease that is strongly associated with inflammation. The percent of C 12 FDG + PBMCs and age‐related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin. These results demonstrate quantifiable measurements in a large group of participants that could create a composite score of healthy aging sensitive enough to detect changes following senolytic therapy and may predict age‐related orthopedic decline. Detection of peripheral senescence in PBMCs and subsets using C 12 FDG may be clinically useful for quantifying cellular senescence and determining how and if it plays a pathological role in osteoarthritic progression.